The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -32,588 | -19,300 | -25,579 | -52,293 |
| Unrealized foreign currency gain | - | - | 0 | 0 |
| Change in fair value of tranche rights | - | - | 0 | 0 |
| Depreciation | 33 | 42 | 40 | 86 |
| Stock-based compensation | 4,466 | 1,308 | 3,614 | 3,941 |
| Non-cash lease expense | 151 | 341 | 48 | 108 |
| Change in fair value of tranche rights | - | 0 | - | - |
| Fees expensed as part of january 2024 financing | - | 0 | 0 | 0 |
| Foreign currency loss | - | 0 | - | - |
| Other current assets and prepaid expenses | -5,214 | 3,116 | -384 | 429 |
| Accounts payable | 1,091 | 2,164 | -31 | -896 |
| Accrued expenses | 4,208 | -398 | 1,428 | 3,447 |
| Other liabilities | 273 | 16 | 6 | -231 |
| Operating lease liability | -149 | -338 | -50 | -118 |
| Net cash used in operating activities | -17,301 | -19,281 | -20,140 | -46,385 |
| Purchases of property and equipment | 2 | 11 | 67 | 83 |
| Net cash used in investing activities | -2 | -11 | -67 | -83 |
| Proceeds from offering, net of issuance costs-May2025PIPETransaction | - | - | 0 | 60,661 |
| Proceeds from offering, net of issuance costs-January2024PIPETransaction | - | - | 0 | 0 |
| Proceeds from offering, net of issuance costs-April2025PIPETransaction | - | - | 0 | 4,734 |
| Proceeds from january 2024 financing, net of issuance costs-January2024PIPETransaction | - | 0 | - | - |
| Proceeds from public offering of common stock through at the market offering, net of issuance costs | - | 0 | 0 | 0 |
| Proceeds from shares issued in connection with the company's employee stock purchase plan | - | 59 | 0 | 123 |
| Proceeds from february 2026 private placement, net of issuance costs | 187,263 | - | - | - |
| Proceeds from january 2024 financing, net of issuance costs-May2025PIPETransaction | - | 60,661 | - | - |
| Proceeds from exercise of series b warrants, net of issuance costs-Pre Funded Warrants | 2 | - | - | - |
| Proceeds from january 2024 financing, net of issuance costs-April2025PIPETransaction | - | 4,734 | - | - |
| Proceeds from exercise of series b warrants, net of issuance costs-Series BWarrants | 1,377 | - | - | - |
| Net cash provided by financing activities | 188,642 | 59 | 0 | 65,518 |
| Effect of exchange rate changes on cash and cash equivalents | -193 | -416 | 29 | 592 |
| Net change in cash and cash equivalents | 171,146 | -19,649 | -20,178 | 19,642 |
| Cash and cash equivalents, beginning of period | 15,483 | 35,132 | 35,668 | - |
| Cash and cash equivalents, end of period | 186,629 | 15,483 | 35,132 | - |
IMMUNIC, INC. (IMUX)
IMMUNIC, INC. (IMUX)